Clin Pharmacokinet. 2021 Sep 27; doi: 10.1007/s40262-021-01073-3. Epub 2021 Sep 27.

Clinical Pharmacokinetics and Pharmacodynamics of the Selective Progesterone Receptor Modulator Vilaprisan: A Comprehensive Overview.

Clinical pharmacokinetics

Marcus-Hillert Schultze-Mosgau, Bart A Ploeger, Matthias Frei, Joachim Höchel, Antje Rottmann

PMID: 34569009 DOI: 10.1007/s40262-021-01073-3

Abstract

Vilaprisan is a highly potent selective progesterone receptor modulator in development for the treatment of symptomatic uterine fibroids and endometriosis. Its pharmacokinetics are characterized by rapid absorption, almost complete bioavailability, and dose-proportional exposure. The intrinsic factors of age, bodyweight, and race have no clinically relevant effect on the pharmacokinetics and pharmacodynamics of vilaprisan and do not warrant a dose adjustment. Similarly, vilaprisan can be used in patients with mild or moderate renal or hepatic impairment without dose adjustment, but its use is not recommended in patients with severe organ impairment. Vilaprisan has no perpetrator potential on cytochrome P450 (CYP) enzymes or transporters and therefore restrictions in the concomitant use of their substrates are not required. Nonetheless, because it is a sensitive CYP3A4 substrate itself, concomitant use of vilaprisan with strong CYP3A inhibitors or inducers is not recommended. However, there is no risk for QTc prolongation when vilaprisan and a strong CYP3A inhibitor are administered concomitantly, as indicated by a vilaprisan concentration-QTc response analysis across all studies with triplicate electrocardiogram measurements. Furthermore, due to its mode of action, vilaprisan is also not recommended to be used together with progestin-containing oral contraceptives. Vilaprisan shows a steep exposure-response relationship for inducing amenorrhea in patients with uterine fibroids experiencing heavy menstrual bleeding. Based on simulations, a dose of 2 mg/day is expected to induce a maximum bleeding reduction and was thus selected for phase III.

© 2021. The Author(s).

References

1. Wagenfeld A, Saunders PTK, Whitaker L, Critchley HOD. Selective progesterone receptor modulators (SPRMs): progesterone receptor action, mode of action on the endometrium and treatment options in gynecological therapies. Expert Opin Ther Targets. 2016;20:1045–54. https://doi.org/10.1080/14728222.2016.1180368 . - PubMed
2. Stewart EA, Cookson CL, Gandolfo RA, Schulze-Rath R. Epidemiology of uterine fibroids: a systematic review. BCOG. 2017;124:1501–12. https://doi.org/10.1111/1471-0528.14640 . - PubMed
3. Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol. 2003;188:100–7. https://doi.org/10.1067/mob.2003.99 . - PubMed
4. Levy G, Hill MJ, Beall S, Zarek SM, Segars JH, Catherino WH. Leiomyoma: genetics, assisted reproduction, pregnancy and therapeutic advances. J Assist Reprod Genet. 2012;29:703–12. https://doi.org/10.1007/s10815-012-9784-0 . - PubMed
5. Ali M, Al-Hendy A. Uterine fibroid therapy: the pharmacokinetic considerations. Expert Opin Drug Metab Toxicol. 2018;14:887–9. https://doi.org/10.1080/17425255.2018.1506766 . - PubMed
6. Ciebiera M, Vitale SG, Ferrero S, Vilos GA, Barra F, Caruso S, et al. Vilaprisan, a new selective progesterone receptor modulator in uterine fibroid pharmacotherapy—will it really be a breakthrough? Curr Pharm Des. 2020;26:300–9. https://doi.org/10.2174/1381612826666200127092208 . - PubMed
7. Charalabidis A, Sfouni M, Bergström C, Macheras P. The Biopharmaceutics Classification System (BCS) and the Biopharmaceutics Drug Disposition Classification System (BDDCS): beyond guidelines. Int J Pharm. 2019;566:264–81. https://doi.org/10.1016/j.ijpharm.2019.05.041 . - PubMed
8. Wagenfeld A, Bone W, Schwede W, Fritsch M, Fischer OM, Moeller C. BAY 1002670: a novel, highly potent and selective progesterone receptor modulator for gynaecological therapies. Hum Reprod. 2013;28:2253–64. https://doi.org/10.1093/humrep/det247 . - PubMed
9. Wagenfeld A, Schulz A, Schultze-Mosgau M, Schuett B, Machens K, Rohde B. Exploratory analysis of molecular pharmacodynamic effects of vilaprisan in the endometrium. Fertil Steril. 2018;110:e134–5. https://doi.org/10.1016/j.fertnstert.2018.07.399 . - PubMed
10. Liu H, Jiang J, Chen Z, Zhang Y, Li J, Hoechel J, et al. Pharmacokinetics and safety of the selective progesterone receptor modulator vilaprisan in Chinese healthy postmenopausal women. Clin Pharmacol Drug Dev. https://doi.org/10.1002/cpdd.851 (Epub 27 Jul 2020). - PubMed
11. Schultze-Mosgau M-H, Höchel J, Prien O, Zimmermann T, Brooks A, Bush J, Rottmann A. Characterization of the pharmacokinetics of vilaprisan: bioavailability, excretion, biotransformation, and drug–drug interaction potential. Clin Pharmacokinet. 2018;57:1001–15. https://doi.org/10.1007/s40262-017-0607-4 . - PubMed
12. Schultze-Mosgau M-H, Schuett B, Hafner F-T, Zollmann F, Kaiser A, Hoechel J, Rohde B. Pharmacokinetics and safety of the selective progesterone receptor modulator vilaprisan in healthy postmenopausal women. Int J Clin Pharmacol Ther. 2017;55:16–24. https://doi.org/10.5414/CP202756 . - PubMed
13. Schultze-Mosgau M-H, Kaiser A, Zollmann FS. Effect of food intake on the pharmacokinetics of the selective progesterone receptor modulator vilaprisan: a randomized clinical study in healthy postmenopausal women. Clin Pharmacol Drug Dev. https://doi.org/10.1002/cpdd.876 (Epub 5 Oct 2020). - PubMed
14. Schadt S, Simon S, Kustermann S, Boess F, McGinnis C, Brink A, et al. Minimizing DILI risk in drug discovery—a screening tool for drug candidates. Toxicol In Vitro. 2015;30:429–37. https://doi.org/10.1016/j.tiv.2015.09.019 . - PubMed
15. Esteve JLC, Acosta R, Pérez Y, Campos R, Hernández AV, Texidó CS. Treatment of uterine myoma with 5 or 10mg mifepristone daily during 6 months, post-treatment evolution over 12 months: double-blind randomised clinical trial. Eur J Obstet Gynecol Reprod Biol. 2012;161:202–8. https://doi.org/10.1016/j.ejogrb.2011.12.018 . - PubMed
16. Xiao Y, Zhu Y, Yu S, Yan C, Ho RJY, Liu J, et al. Thirty-day rat toxicity study reveals reversible liver toxicity of mifepristone (RU486) and metapristone. Toxicol Mech Methods. 2016;26:36–45. https://doi.org/10.3109/15376516.2015.1118715 . - PubMed
17. Pohl O, Zobrist RH, Gotteland J-P. The clinical pharmacology and pharmacokinetics of ulipristal acetate for the treatment of uterine fibroids. Reprod Sci. 2015;22:476–83. https://doi.org/10.1177/1933719114549850 . - PubMed
18. Sitruk-Ware R, Spitz IM. Pharmacological properties of mifepristone: toxicology and safety in animal and human studies. Contraception. 2003;68:409–20. https://doi.org/10.1016/s0010-7824(03)00171-9 . - PubMed
19. Morris D, Podolski J, Kirsch A, Wiehle R, Fleckenstein L. Population pharmacokinetics of telapristone (CDB-4124) and its active monodemethylated metabolite CDB-4453, with a mixture model for total clearance. AAPS J. 2011;13:665–73. https://doi.org/10.1208/s12248-011-9304-7 . - PubMed
20. Liu R, Yu X, Wallqvist A. Data-driven identification of structural alerts for mitigating the risk of drug-induced human liver injuries. J Cheminform. 2015;7:4. https://doi.org/10.1186/s13321-015-0053-y . - PubMed
21. Kalgutkar AS. Should the incorporation of structural alerts be restricted in drug design? An analysis of structure-toxicity trends with aniline-based drugs. Curr Med Chem. 2015;22:438–64. https://doi.org/10.2174/0929867321666141112122118 . - PubMed
22. Möller C, Bone W, Cleve A, Klar U, Rotgeri A, Rottmann A, et al. Discovery of vilaprisan (BAY 1002670): a highly potent and selective progesterone receptor modulator optimized for gynecologic therapies. ChemMedChem. 2018;13:2271–80. https://doi.org/10.1002/cmdc.201800487 . - PubMed
23. Sutter G, Frei M, Schultze-Mosgau M-H, Petersdorf K, Seitz C, Ploeger B. Assessment of the safe and efficacious dose of the selective progesterone receptor modulator vilaprisan for the treatment of patients with uterine fibroids by exposure-response modelling and simulation. Br J Clin Pharmacol. https://doi.org/10.1111/bcp.15014 (Epub 30 Jul 2021). - PubMed
24. Schütt B, Kaiser A, Schultze-Mosgau M-H, Seitz C, Bell D, Koch M, Rohde B. Pharmacodynamics and safety of the novel selective progesterone receptor modulator vilaprisan: a double-blind, randomized, placebo-controlled phase 1 trial in healthy women. Hum Reprod. 2016;31:1703–12. https://doi.org/10.1093/humrep/dew140 . - PubMed
25. Schütt B, Schultze-Mosgau M-H, Draeger C, Chang X, Löwen S, Kaiser A, Rohde B. Effect of the novel selective progesterone receptor modulator vilaprisan on ovarian activity in healthy women. J Clin Pharmacol. 2018;58:228–39. https://doi.org/10.1002/jcph.998 . - PubMed
26. Bradley LD, Singh SS, Simon J, Gemzell-Danielsson K, Petersdorf K, Groettrup-Wolfers E, et al. Vilaprisan in women with uterine fibroids: the randomized phase 2b ASTEROID 1 study. Fertil Steril. 2019;111:240–8. https://doi.org/10.1016/j.fertnstert.2018.10.012 . - PubMed
27. Gemzell-Danielsson K, Heikinheimo O, Zatik J, Poka R, Rechberger T, Hudecek R, et al. Efficacy and safety of vilaprisan in women with uterine fibroids: Data from the phase 2b randomized controlled trial ASTEROID 2. Eur J Obstet Gynecol Reprod Biol. 2020;252:7–14. https://doi.org/10.1016/j.ejogrb.2020.05.043 . - PubMed
28. Brill MJ, van Rongen A, van Dongen EP, van Ramshorst B, Hazebroek EJ, Darwich AS, et al. The pharmacokinetics of the CYP3A substrate midazolam in morbidly obese patients before and one year after bariatric surgery. Pharm Res. 2015;32:3927–36. https://doi.org/10.1007/s11095-015-1752-9 . - PubMed
29. Schultze-Mosgau M-H, Lasseter KC, Marbury T, Loewen S, Riecke K. Pharmacokinetics and safety of the novel selective progesterone receptor modulator vilaprisan in participants with renal impairment. J Clin Pharmacol. 2020;60:1030–8. https://doi.org/10.1002/jcph.1608 . - PubMed
30. Chattopadhyay N, Riecke K, Ligges S, Zimmermann T, Halabi A, Schultze-Mosgau M-H. Effect of hepatic impairment on the pharmacokinetics of vilaprisan: an open-label, single-dose, parallel-group study. Br J Clin Pharmacol. 2019;85:2011–21. https://doi.org/10.1111/bcp.13992 . - PubMed
31. Brill MJE, Diepstraten J, van Rongen A, van Kralingen S, van den Anker JN, Knibbe CAJ. Impact of obesity on drug metabolism and elimination in adults and children. Clin Pharmacokinet. 2012;51:277–304. https://doi.org/10.2165/11599410-000000000-00000 . - PubMed
32. Chattopadhyay N, Kanacher T, Casjens M, Frechen S, Ligges S, Zimmermann T, et al. CYP3A4-mediated effects of rifampicin on the pharmacokinetics of vilaprisan and its UGT1A1-mediated effects on bilirubin glucuronidation in humans. Br J Clin Pharmacol. 2018;84:2857–66. https://doi.org/10.1111/bcp.13750 . - PubMed
33. Hoogland HJ, Skouby SO. Ultrasound evaluation of ovarian activity under oral contraceptives. Contraception. 1993;47(6):583–590. - PubMed
34. Schultze-Mosgau M-H, Schütt B, Draeger C, Casjens M, Loewen S, Zimmermann T, Rohde B. The effects of vilaprisan on the pharmacodynamics and pharmacokinetics of a combined oral contraceptive—a randomized controlled trial. Br J Clin Pharmacol. 2021;87:925–36. https://doi.org/10.1111/bcp.14443 . - PubMed
35. Insler V, Melmed H, Eichenbrenner I, Serr DM, Lunenfeld B. The Cervical Score. A simple semiquantitative method for monitoring of the menstrual cycle. Int J Gynecol Obstet. 1972;10:223–8. - PubMed
36. Kanacher T, Frechen S, Wendl T, Block M, Rottmann A, Chattopadhyay N, et al. Towards a detailed understanding of the impact of drug drug interactions on vilaprisan exposure by PBPK modeling & simulation. Poster presented at the DDI Workshop at Marbach Castle, Öhningen, Germany; 2017. - PubMed

Publication Types

• Journal Article
• Review